Claire Manuszak, BS, discusses a phase I study (NCT03495323) with prexasertib (LY2606368) and LY3300054 in ovarian cancer.
Claire Manuszak, BS
Advertisement
Articles by Claire Manuszak, BS
Claire Manuszak, BS, discusses the rationale to combine prexasertib (LY2606368) and LY3300054 in patients with high-grade serous ovarian cancer.
Advertisement
Latest Updated Articles
The Rationale to Combine Prexasertib With LY3300054 in Ovarian CancerFebruary 10th 2020
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma
3
Five Under 5: Top Oncology Videos for the Week of 9/20
4
FDA Grants Priority Review to Perioperative Durvalumab Plus Neoadjuvant Enfortumab Vedotin in MIBC
5